OraSure Technologies (NASDAQ:OSUR) Upgraded by StockNews.com to “Buy”

StockNews.com upgraded shares of OraSure Technologies (NASDAQ:OSUR) from a hold rating to a buy rating in a research note released on Friday.

Separately, Evercore ISI boosted their price target on shares of OraSure Technologies from $4.50 to $5.00 and gave the company an in-line rating in a research report on Wednesday, August 7th. Two research analysts have rated the stock with a hold rating and two have given a buy rating to the company. Based on data from MarketBeat, OraSure Technologies currently has an average rating of Moderate Buy and an average target price of $6.67.

OraSure Technologies Stock Down 1.2 %

OraSure Technologies stock opened at $4.09 on Friday. OraSure Technologies has a 52-week low of $3.91 and a 52-week high of $8.45. The firm has a market capitalization of $302.49 million, a price-to-earnings ratio of 13.63 and a beta of 0.05. The company has a fifty day simple moving average of $4.30 and a 200-day simple moving average of $4.72.

OraSure Technologies (NASDAQ:OSUR) last released its earnings results on Tuesday, August 6th. The medical instruments supplier reported $0.03 earnings per share (EPS) for the quarter. OraSure Technologies had a net margin of 9.88% and a return on equity of 9.15%. The business had revenue of $54.34 million during the quarter, compared to analyst estimates of $53.35 million. On average, research analysts anticipate that OraSure Technologies will post -0.11 EPS for the current fiscal year.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the stock. SG Americas Securities LLC acquired a new position in OraSure Technologies in the first quarter valued at about $72,000. Mackenzie Financial Corp acquired a new stake in shares of OraSure Technologies during the second quarter worth about $72,000. Tocqueville Asset Management L.P. lifted its position in shares of OraSure Technologies by 20.0% during the first quarter. Tocqueville Asset Management L.P. now owns 15,089 shares of the medical instruments supplier’s stock worth $93,000 after purchasing an additional 2,512 shares in the last quarter. Shikiar Asset Management Inc. acquired a new stake in shares of OraSure Technologies during the second quarter worth about $96,000. Finally, SkyView Investment Advisors LLC lifted its position in shares of OraSure Technologies by 100.0% during the second quarter. SkyView Investment Advisors LLC now owns 24,000 shares of the medical instruments supplier’s stock worth $102,000 after purchasing an additional 12,000 shares in the last quarter. Institutional investors and hedge funds own 93.50% of the company’s stock.

OraSure Technologies Company Profile

OraSure Technologies, Inc, together with its subsidiaries, provides point-of-care and home diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services in the United States, Europe, and internationally. The company’s products include InteliSwab COVID-19 rapid test, InteliSwab COVID-19 rapid test pro, InteliSwab COVID-19 rapid test rx, OraQuick Rapid HIV test, OraQuick In-Home HIV test, OraQuick HIV self-test, OraQuick HCV rapid antibody test, OraQuick Ebola rapid antigen test, OraSure oral fluid collection device used in conjunction with screening and confirmatory tests for HIV-1 antibodies; Intercept drug testing systems; immunoassay tests and reagents; and Q.E.D.